BioAge Labs, Inc (BIOA NASDAQ) stock market data APIs
$7.8525
-0.11(-1.4%)
as of November 14, 2025
Try our APIs with
free plan!
BioAge Labs, Inc Financial Data Overview
Price chart is built with
Anychart
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It develops BGE-102, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Prev. Close
7.8525
Open
7.7391
High
8.0619
Low
7.6036
52 wk Range
2.88-20.37
Market Cap
277 M
P/E Ratio
0.5672
Shares Outstanding
35 855 K
Revenue
5 917 K
EPS
-0.56
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with BioAge Labs, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BioAge Labs, Inc data using free add-ons & libraries
Get BioAge Labs, Inc Fundamental Data
BioAge Labs, Inc Fundamental data includes:
- Net Revenue: 5 917 K
- EBITDA: -89 528 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.5137
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioAge Labs, Inc News
New
Why BioArctic (OM:BIOA B) Is Up 6.3% After Leqembi Royalties and Novartis Partnership Boost Sales
BioArctic AB reported its third quarter 2025 results, highlighting SEK133.35 million in sales compared to SEK76.63 million a year earlier, alongside a net loss of SEK86.87 million due to increased R&D...
BioAge Labs to Present at Jefferies Global Healthcare Conference in London
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for...
Citigroup Says This Obesity Drugmaker's Stock Is Now a Buy
Key Points The weight-loss drug market is already enormous, but could nearly double in size by 2035. BioAge Labs is still years away from revenue and even more years away from actual profits. Investo...
BioAge Labs Stock Just Soared. Does It Have More Fuel to Climb Higher?
Key Points BioAge Labs' stock recently jumped, and a Wall Street analyst thinks it has further to climb. The company is focusing on a source of inflammation in the brain as a way to regulate appetit...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
